MX2015011109A - Composiciones estables de activador de glucoquinasa. - Google Patents

Composiciones estables de activador de glucoquinasa.

Info

Publication number
MX2015011109A
MX2015011109A MX2015011109A MX2015011109A MX2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A MX 2015011109 A MX2015011109 A MX 2015011109A
Authority
MX
Mexico
Prior art keywords
stable
glucokinase activator
activator compositions
glucokinase
compositions
Prior art date
Application number
MX2015011109A
Other languages
English (en)
Spanish (es)
Inventor
Mahendra G Dedhiya
Yun Mo
Anil Chhettry
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2015011109A publication Critical patent/MX2015011109A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015011109A 2013-03-04 2014-02-28 Composiciones estables de activador de glucoquinasa. MX2015011109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772022P 2013-03-04 2013-03-04
PCT/US2014/019349 WO2014137797A2 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Publications (1)

Publication Number Publication Date
MX2015011109A true MX2015011109A (es) 2015-11-16

Family

ID=50424705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011109A MX2015011109A (es) 2013-03-04 2014-02-28 Composiciones estables de activador de glucoquinasa.

Country Status (11)

Country Link
US (1) US20160015638A1 (enExample)
EP (1) EP2964198A2 (enExample)
JP (1) JP6441828B2 (enExample)
KR (1) KR20150123838A (enExample)
CN (1) CN105050585A (enExample)
AU (1) AU2014226290B2 (enExample)
CA (1) CA2903433A1 (enExample)
HK (1) HK1213780A1 (enExample)
IL (1) IL240735A0 (enExample)
MX (1) MX2015011109A (enExample)
WO (1) WO2014137797A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359313B2 (en) 2010-05-26 2016-06-07 Vtv Therapeutics Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
KR102371364B1 (ko) 2012-05-17 2022-03-07 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
CN115715762A (zh) * 2016-12-15 2023-02-28 华领医药技术(上海)有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3185831A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
KR20230048502A (ko) * 2020-06-08 2023-04-11 브이티브이 테라퓨틱스 엘엘씨 {2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐}-아세트산의 염 또는 공결정 및 그의 용도
CA3181665A1 (en) * 2020-06-08 2021-12-16 Jing TENG Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
EP1503737B1 (en) * 2002-05-06 2009-01-07 Elan Pharma International Limited Nanoparticulate nystatin formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2003103633A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
AU2005203930C1 (en) * 2004-01-06 2012-02-23 Vtv Therapeutics Llc Heteroaryl-ureas and their use as glucokinase activators
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
AU2005316473B2 (en) * 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
AU2006204083A1 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
MX2007010394A (es) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
CN101175481A (zh) * 2005-03-17 2008-05-07 伊兰制药国际有限公司 纳米颗粒免疫抑制化合物的可注射的组合物
MX2007011495A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones de bifosfonato en nanoparticulas.
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CN101212954A (zh) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
EP2040675A1 (en) * 2006-05-30 2009-04-01 Elan Pharma International Limited Nanoparticulate posaconazole formulations
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US20090028680A1 (en) * 2007-07-27 2009-01-29 Kling Troy L Intermediate apparatus for towing utility vehicles
GEP20135783B (en) * 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
US8054567B2 (en) * 2008-07-23 2011-11-08 Hitachi High-Technologies Corporation Method for measuring write/read width of a composite magnetic head and a measuring device using the method
CN102802609A (zh) * 2009-06-18 2012-11-28 雅培制药有限公司 稳定的纳米颗粒药物悬浮液
EP2442794A1 (en) * 2009-06-19 2012-04-25 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
US9359313B2 (en) * 2010-05-26 2016-06-07 Vtv Therapeutics Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

Also Published As

Publication number Publication date
US20160015638A1 (en) 2016-01-21
IL240735A0 (en) 2015-10-29
HK1213780A1 (zh) 2016-07-15
CA2903433A1 (en) 2014-09-12
AU2014226290A1 (en) 2015-10-08
JP6441828B2 (ja) 2018-12-19
JP2016513625A (ja) 2016-05-16
CN105050585A (zh) 2015-11-11
KR20150123838A (ko) 2015-11-04
WO2014137797A3 (en) 2014-10-30
AU2014226290B2 (en) 2018-11-15
EP2964198A2 (en) 2016-01-13
WO2014137797A2 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
MX2015011109A (es) Composiciones estables de activador de glucoquinasa.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2021001231A (es) Compuestos heterociclicos y sus usos.
ZA201507627B (en) P2x7 modulators
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2015012416A (es) Compuestos heterociclicos y sus usos.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
IN2013MU03641A (enExample)
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
MX2015016603A (es) Composiciones de corticosteroides.
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
EP3326652A4 (en) Pharmaceutical composition for oral administration comprising high concentration taxane
IN2013CH05770A (enExample)